Dr. Luo has over 20 years of experience in the biomedical industry. Before founding Denovo Biopharma, Dr. Luo worked at Ligand Pharmaceuticals, where he led and participated in the research and development of multiple second-generation nuclear hormone receptor modulating drugs, worked on the molecular mechanism of hormone receptors, tissue and organ selectivity, and establishment of drug screening trials, and was responsible for formulating and implementing biomarker strategies for multiple drugs at different stages of development. While at Corvas, he was responsible for the development of new protease drug targets. At Incyte Genomics, Dr. Luo was involved in the management of at the time the world’s largest proteome database LifeProt and worked on the research and development of new drug target genes and their splicing variants. He was engaged in the identification and development of new drug targets in the fields of cancer, immune diseases, and angiogenesis at Sugen. He served as a postdoctoral fellow at Howard Hughes Medical Institute of University of California, San Francisco. Dr. Luo holds a PhD in molecular biology and biochemistry from Indiana University.
Wen Luo
